Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8747340 | 0.71 | — | — | |
| SCHEMBL867248 | 0.69 | LMNA (0.32) | LMNA | |
| SCHEMBL9310693 | 0.69 | LMNA (0.32) | LMNA | |
| SCHEMBL5323459 | 0.67 | — | — | |
| SCHEMBL477040 | 0.67 | LMNA (0.30) | LMNA | |
| SCHEMBL17292693 | 0.67 | LMNA (0.30) | LMNA | |
| SCHEMBL6406502 | 0.64 | — | — | |
| SCHEMBL1899752 | 0.64 | — | — | |
| SCHEMBL34678 | 0.64 | — | — | |
| SCHEMBL6872536 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766001-B1 | BUFFERED OXYGEN THERAPEUTIC | NUVOX PHARMA LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-8822549-B2 | Buffered oxygen therapeutic | NUVOX PHARMA LLC | 2014-09-02 | — | — | US | disclosed |
| EP-2766001-A1 | BUFFERED OXYGEN THERAPEUTIC | Nuvox Pharma, LLC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130096204-A1 | Buffered Oxygen Therapeutic | NUVOX PHARMA LLC | 2013-04-18 | — | — | US | disclosed |
| WO-2013056246-A1 | BUFFERED OXYGEN THERAPEUTIC | NUVOX PHARMA L.L.C. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-1015039-B1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070059248-A1 | Oxygen delivery agents and uses for the same | IMARX THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-7105151-B2 | Oxygen delivery agents and uses for the same | IMARX THERAPEUTICS, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1037673-B1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1039834-B1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6028066-A | FOR DELIVERING HIGHER CONCENTRATIONS OF BIOACTIVE AGENTS TO IMPROVE EFFICACY OF THE BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0901793-A1 | Thermal preactivation of gaseous precursor filled compositions | IMARX PHARMACEUTICAL CORP. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998057670-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998051284-A1 | NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998050040-A1 | NOVEL LIPID SOLUBLE STEROID PRODRUGS | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050041-A1 | NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998042383-A1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096204-A1 | Buffered Oxygen Therapeutic | HIF1AN, HIF1A, FGB | LMNA 1449/4885 |
| US-20070059248-A1 | Oxygen delivery agents and uses for the same | VEGFA, PGF, SLCO2A1 | LMNA 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.